Raising an isolated low HDL-C level: Why, how, and when?
Michael Miller, MD
Director, Center for Preventive Cardiology, Department of Medicine and Epidemiology, University of Maryland Medical Center, Baltimore
Address: Michael Miller, MD, Director, Center for Preventive Cardiology, Department of Medicine and Epidemiology, University of Maryland Medical Center, 22 South Greene St., Room 53B06, Baltimore, MD 21201; e-mail: firstname.lastname@example.org
The author has indicated that he has received grant or research support from the Merck, Pfizer, Kos Pharmaceuticals, and AstraZeneca corporations.
ABSTRACTTreating patients with isolated low high-density lipoprotein cholesterol (HDL-C) remains daunting. The decision to treat depends on the individual patient's overall risk for coronary heart disease (CHD). Strategies for raising HDL-C levels can include various lifestyle and drug therapies, which should be tailored to individual patients. While no current therapy is optimal, many can yield modest increases that translate into reduced risk for CHD events.